Patients with hemophilia B face a lifelong need for regular factor IX injections. But in 9 of 10 patients treated with a novel gene therapy, this need was eliminated. "Removing the need for hemophilia ...

A long-acting coagulation factor treatment of patients with hemophilia B is safe and effective for preventing bleeding events, according to an article published online December 4 and in the December ...

Potential Biomarker, Drug Target ID’d for Adult Leukemia Prophylactic rFIXFc, administered every one to two weeks, resulted in low annualized bleeding rates in patients with hemophilia B. (HealthDay ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Due to a mutation in their DNA, patients with haemophilia B either can't produce enough of factor IX – a specific protein that makes blood clot – or lack it entirely. | Credit: Illustration by Stephen ...

Gene therapy is part of an increasingly large collection of research fields: those with a huge, useless backlog of innovations. Gene therapy researchers have spent decades developing amazing, ...